Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602537 · ClinicalTrials.gov registry record · Phase 4
Antidepressant Therapy in Treating Bipolar Type II Major Depression
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT00602537: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00602537 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602537, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will compare the safety and effectiveness of antidepressant therapy versus mood stabilizing therapy in treating people with bipolar type II major depression.
Interventions
- DRUG Venlafaxine
- DRUG Lithium Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602537
The ClinicalTrials.gov registry entry for NCT00602537 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venlafaxine is the first listed.
NCT00602537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602537 about?
NCT00602537 is a clinical study titled "Antidepressant Therapy in Treating Bipolar Type II Major Depression". This study will compare the safety and effectiveness of antidepressant therapy versus mood stabilizing therapy in treating people with bipolar type II major depression.
What is the current status of trial NCT00602537?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2007-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00602537?
The interventions under investigation include: Venlafaxine (DRUG), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT00602537?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.